Regulation - Merck & Co

Filter

Current filters:

Merck & Co

Popular Filters

76 to 84 of 84 results

FDA panel gives unanimous backing for Merck & Co’s Vytorin for some kidney disease patients

04-11-2011

US drug giant Merck & Co (NYSE: MRK) said yesterday that the Endocrinologic and Metabolic Drugs Advisory…

Cardio-vascularMerck & CoNorth AmericaPharmaceuticalRegulationVytorin

FDA clears Merck & Co’s combo diabetes/cholesterol therapy Juvisync

10-10-2011

The US Food and Drug Administration on Friday approved the marketing of the first combination drug to…

Cardio-vascularDiabetesJanuviaJuvisyncMerck & CoNorth AmericaPharmaceuticalRegulationZocor

Two US FDA advisory panels say osteoporosis drugs need label changes

12-09-2011

Experts advising the US Food and Drug Administration have recommended revised labeling for bisphosphonates,…

ActonelAnti-Arthritics/RheumaticsBonvivaFosamaxMerck & CoNorth AmericaPharmaceuticalReclastRegulationRocheWarner Chilcott

Draft guidance from UK's NICE recommends clinical trial for COPD drug Daxas

09-09-2011

New draft guidance from the UK's drug watchdog the National Institute for Health and Clinical Excellence…

DaxasEuropeMerck & CoNycomedPharmaceuticalPricingRegulationRespiratory and Pulmonary

UK’s NICE recommends Merck & Co’s Simponi but not B-MS’s Orencia

26-08-2011

There was mixed news for US drug majors Merck & Co (NYSE: MRK) and Bristol-Myers Squibb (NYSE: BMY) this…

Anti-Arthritics/RheumaticsBristol-Myers SquibbEuropeMerck & CoOrenciaPharmaceuticalPricingRegulationSimponi Injection

AstraZeneca gets EU approval for Axanum; Merck & Co files ridaforolimus with EMA

02-08-2011

Anglo-Swedish drug major AstraZeneca (LSE: AZN) revealed this morning that it has received approval in…

Ariad PharmaceuticalsAstraZenecaAxanumCardio-vascularEuropeMerck & CoOncologyPharmaceuticalRegulationridaforolimus

76 to 84 of 84 results

Back to top